


































Culture shock causes rapid replicative senescence in 
primary MEFs with functional p53, but p53 deficient 
cells are resistant  
 
Cellular senescence is an important defence mechanism 
against tumour metastasis, growth and progression [1, 
2].  Furthermore, in both humans and in mouse models, 
cancers can respond to chemotherapy by a massive 
senescence response followed by tumour cell clearance 
[3-5]. MEFs are a classic model system for studying cell 
senescence and immortalisation, with clear parallels to 
key genetic alterations during human tumourigenesis 
whilst offering expedient advantages over human cell 
cultures when exploring basic molecular mechanisms of 
senescence control and senescence bypass [6, 7].  When 
explanted in vitro MEFs initially continue to replicate, 
but then rapidly undergo stress-associated senescence 
due to in vitro conditions, especially oxidative stress 





































supraphysiological levels of oxygen [8].  DNA damage 
from reactive oxygen species is clearly a key factor in 
this senescence response [8, 9]. As is well known from 
research in several laboratories, cells that sustain 
spontaneous damage to the p53/p19ARF pathway (p14 
in humans) can overcome this replication block, leading 
to gradual outgrowth of an immortalised cell population 
with unlimited growth potential [10-14].   
 
Our MEF cell line library comprises immortalised cell 
lines from cultures of fibroblasts derived from (a) 
embryos of a standard laboratory wild-type mouse 
strain (129/Sv), and (b) embryos from human p53 
knock-in (Hupki) mice, which we constructed for our 
research on p53 biology [15-17].  The original Hupki 
mouse strain [15] harbours normal human p53 gene 
sequences encoding the DNA binding domain and the 
polyproline domain embedded in the endogenous 
murine p53 locus.  This strain is phenotypically normal, 
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responses, including DNA damage induced apoptosis, 
transcriptional transactivation of p53 target genes and 
stress-induced cellular senescence.  Curiously, a mouse 
strain in which the entire p53 sequence was replaced by 
the human counterpart lost wild-type p53 function due 
to abnormal interactions with the p53 negative regulator 
Mdm2 [18]. The Hupki strain is not p53-deficient, and 
can be used as a source of primary MEFs, thus allowing 
the extensive literature on MEF senescence bypass, and 
the database of human tumour suppressor mutations to 
be linked to specific mutations that support senescence 
bypass.  Using this approach, we have shown that the 
basic features of stress-induced senescence and 
immortalisation are comparable in MEFs from standard 
strain wild-type (WT) mice and Hupki mice. Studies 
from our laboratory with several hundred immortalised 
Hupki MEF cell lines have shown that the genetic 
alterations in p53 that lead to senescence bypass of 
MEFs are typical of human tumours. Missense point 
mutations in p53 and p19/ARF silencing by biallelic 


































most common routes to spontaneous p53/p19ARF 
pathway inactivation in immortalised MEFs 
identified thus far ([16, 19, 20]  and unpublished 
observations). 
 
Whilst the prevalence of cell lines immortalised by 
p19/ARF biallelic deletion or p53 mutation was not 
unexpected (up to 50 % of cell lines, depending on 
immortalisation protocols), we were surprised to find 
that a significant fraction of cell lines (derived both 
from WT and Hupki primary cells) appeared to have 
retained WT p53 and p19/ARF expression, as examined 
by DNA sequencing or PCR amplification and promoter 
methylation analyses,  respectively ([20] and unpub-
lished).  Probing by immunofluorochemistry for p53 
nuclear accumulation and induction of p21/WAF1 
following exposure of these cell lines to the DNA 
damaging agent doxorubicin (Figure 1), as well as 
detection of p19/ARF protein by immunoblotting [20] 
support the p53, p19/ARF wild-type status of these cell 
lines.  What might then be the genetic alterations that 
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suppressor haploinsufficiency in promoting cell growth 
(see insightful review by Quon and Berns, 2001) [21, 22].    
Contrary to the original 2-hit paradigm for tumour 
suppressor genes, where both alleles must be inactivated 
to elicit a growth promoting phenotype, ample evidence 
from in vivo and in vitro studies and human tumour 
analyses demonstrates that not only the absence, but 
also the moderate reduction of tumour suppressor gene 
products can be sufficient to alter growth phenotype.  In 
the case of MEFs, as expected, cells from p53 null mice 
fail to senesce when explanted in vitro under standard 
culture conditions, but cells from heterozygous Hupki 
mice (progeny of Hupki and p53 null mice) also 
continue to grow when explanted, with only a brief 
slowing of doubling time after the first several passages 
(unpublished observations).  Some of these immortal 
cultures eventually do reveal loss of the WT allele with 
continued passaging, but others retain the original 
unmutated p53 allele. This suggests that the presence of 
only one WT allele in primary explanted MEFs may be 
sufficient to bypass senescence initially.  Conceivably, 
as passage number increases, so will the chances that 
the WT allele is eventually discarded, possibly 
provoking a jump in growth rate, as we have noted for 
some slow-growing MEF cell lines.    
  
Some of the MEF cell lines from (homozygous) WT or 
Hupki mice that we have examined and tentatively 
classified as p53 and p19/ARF wild-type thus may in 
fact have only one normal allele of these suppressor 
genes, having suffered loss of one copy in vitro 




Given that at least half of the spontaneously arising 
>100 MEF cell lines we examined for p53 and p19/ARF 
aberrations appeared to have overcome senescence 
block upon explanting in vitro by mechanisms other 
than the 2 canonical genetic events (p53 mutation; p19 
biallelic deletion), there could well be various 
alternative pathways to immortalisation not directly 
involving damage to the immediate p53/p19ARF axis. 
 
Considerable effort is underway to identify the key 
regulators of senescence and immortalisation. Since the 
process of senescence bypass provides an intrinsic 
phenotypic readout of functionality and automatically 
generates cell lines amenable to subsequent analysis, 
reverse genetics is a powerful approach to deciphering 
the important molecular events involved in senescence 
control [23]. Several large-scale screens for genes 
involved in senescence/senescence bypass have been 
performed, including both gain-of-function screens 
involving the ectopic expression of cDNA libraries as 
well as loss-of-function screens involving the 
expression of antisense cDNA libraries and shRNA 
libraries. These screens have been performed in human 
and mouse cell models of both replicative and 
oncogene-induced senescence and each approach has 
identified different genes involved in senescence, 
providing novel and sometimes unexpected insights into 
the process (Table 1). Reassuringly, well established 
players in the master regulatory pathways of senescence 
(for example p53) have also been identified in these 
screens [24, 25]. Indeed, inactivation of p53 is often 
used as a positive control in such experiments [24, 26]. 
While p53 knock-down in senescent MEFs has been 
shown to reverse senescence [27], this may or may not 
be true of other genes involved in senescence which 
may require inactivation or expression prior to the 
acquisition of senescence. 
 
The role of p53 mutation/p19ARF deletion in 
senescence bypass in MEFs reflects the importance of 
the p53/p19ARF axis as a master regulatory pathway of 
senescence in these cells.  What is apparent from 
genetic screening, as well as from other complementary 
work, is that many of the novel senescence-associated 
genes identified can also impact on this key pathway, 
both upstream and downstream of p53 [24, 26, 28-31].  
The p16/pRb pathway, another senescence master 
regulator, is also commonly affected by novel 
senescence-associated molecules [28, 32].  A number of 
additional interacting signaling pathways have been 
implicated in the induction or bypass of senescence 
including the RAS/MAPK pathway [25, 33, 34], the 
AKT pathway [35-37] and the JNK pathway [38, 39], 
although the relative contribution of these to the 
senescent phenotype appears to be dependent on 
species, cell type and the pro-senescence stimulus.   
 
Concluding remarks: Senescence – good or bad? 
 
An entirely new aspect to the importance of cellular 
senescence has recently surfaced from experiments to 
produce iPS (induced pluripotent stem) cells from 
embryonic fibroblasts.  It has been shown that 
senescence provides a progressive barrier to 
conversion of primary MEFs (and indeed other types 
of differentiated cells) to pluripotency.  Crucially, 
disruption of the p53/p19ARF signalling axis greatly 
increased efficiency of their conversion [40, 41].   
Furthermore, genetic ablation of p53 in cells normally 
considered refractory to reprogramming into 
pluripotent stem cells can overcome this block [40].  
Clearly, senescence is a key process to target in 
optimising strategies to enhance somatic cell re-
programming.  Identification of factors influencing se-
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compromising  genetic  integrity, expediting potential 
























































Potential senescence-associated pathway/mechanism of 
action 
Biological Function  Refe-
rence 
Cell type 
BCL6  inhibition  Induces cyclin D1 expression and 
renders cells unresponsive to antiproliferative signals from the 
p19(ARF)-p53 pathway 
Transcription factor  [29]  MEFs, human B 
cells 
Bub1  inhibition  Bub1 RNAi induces senescence.  Bub1 expression does not 
extend lifespan 






Csn2  promotion  Inactivation inhibits p53 transcriptional activity and confers 
resistance to both p53- and p16INK4a-induced proliferation 
arrest 
Component of the Cop9 
signalosome 
[28]  Primary MEFs 
Brf1  promotion  Inhibition of p53 transcription and reduction p16ink4a-
induced arrest 
Subunit of the RNA 
polymerase II complex 
[28] Primary  MEFs 
Aldose 
Reductase 
promotion  Inhibition of p53 transcription and reduction p16ink4a-
induced arrest 
Metabolic enzyme – 
glucose metabolism 
[28]  Primary MEFs 
Tid1  induction  Tid1 is a repressor of NF-κB signaling  DNA-J like protein which 
functions as a co-
chaperone 
[43] Rat  embryo 
fibroblasts 
hDRIL1  inhibition  Renders primary MEFs unresponsive to RAS(V12)-induced 
anti-proliferative signaling by p19(ARF)/p53/p21(CIP1), as 
well as by p16(INK4a) 
Binds E2F1 and induces Cyclin E1 




CBX7  inhibition  Controls cellular lifespan through regulation of both the 
p16(Ink4a)/Rb and the Arf/p53 pathways 
Represses INK4a-ARF locus 
Transcription factor  [44]  Normal human 
prostate epithelial 
cells 
LPA(2)  inhibition  E2F induction  Phospholipid receptor  [45]  Mouse neuronal 
cells 
Dbs  inhibition  E2F induction  Rho-specific guanine 
nucleotide exchange factor 
[45] Mouse  neuronal 
cells 
TBX2  inhibition  TBX2 represses the Cdkn2a (p19(ARF)) promoter  Transcription factor  [31]  Bmi1
-/- MEFs 
 
TBX3  inhibition  TBX-3 potently represses expression of both mouse p19(ARF) 
and human p14(ARF) 
Transcription factor  [30]  Mouse neuronal 
cells 
Topo1  promotion  DNA damage-ATM-p53  Nuclear enzyme regulating 
DNA structure 
Relaxes positively and 
negatively supercoiled 
DNA 
[26]  Normal human cells 
IGFBP7  promotion MEK,  ERK  pathway 
In Brafv600E-mediated senescence, IGFBP7 inhibits BRAF-
MEK-ERK signaling by inducing RKIP, which prevents 
BRAF from phosphorylating MEK 
Ser/Thr protein kinase, 
oncogene 
Growth factor receptor 
[25, 46]  Human primary 
fibroblasts, 
melanocytes 
KLF4  promotion  p53 pathway 
Suppresses the expression of p53 by directly acting on its 
promoter 
Induces p21 





SAHH  promotion p53  pathway 









promotion  p53 pathway 
CXCR2 knock-down alleviates both replicative and oncogene-
induced senescence and diminishes the DNA-damage 
response. 
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